<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04268498</url>
  </required_header>
  <id_info>
    <org_study_id>20201316</org_study_id>
    <nct_id>NCT04268498</nct_id>
  </id_info>
  <brief_title>A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma</brief_title>
  <acronym>ADVANCE</acronym>
  <official_title>Phase 2, Open-Label Randomized Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone vs Carfilzomib, Lenalidomide, and Dexamethasone vs Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to find out whether carfilzomib, lenalidomide, and dexamethasone&#xD;
      (KRD) or KRD and Daratumumab (KRD+DARA) might be safer and more effective ways of controlling&#xD;
      multiple myeloma than the stand or care treatment, which is lenalidomide, bortexomib, and&#xD;
      dexamethasone (VRD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 11, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2027</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Minimal Residual Disease (MRD) Negativity</measure>
    <time_frame>Up to 32 weeks</time_frame>
    <description>MRD will be assessed from bone marrow samples.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Overall survival is defined as the time from date of randomization to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>PFS is defined as time from date of randomization to time of progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival (EFS)</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>EFS is defined as time from date of randomization to the time of 1) achieving a PR or less with the first four cycles of therapy, 2) transplant, 3) progression, or 4) death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Response</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Rate of Response will be reported as the percentage of participants achieving a response of: a) Partial Response (PR) or better, b) Very Good Partial Response (VGPR) or better and c) Complete Response (CR) and Stringent Complete Response (sCR). Responses will be evaluated from participant serum, urine and bone marrow samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of MRD Negativity as best response</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>MRD will be evaluated from bone marrow samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment related toxicity</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>Toxicity will be evaluated by treating physician using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal Residual Disease (MRD) Negativity</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>MRD Negativity using bone marrow and blood samples</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">462</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Arm A - Bortezomib, Lenalidomide and Dexamethasone (VRD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive Bortezomib, Lenalidomide and Dexamethasone on a 21 day treatment cycle. Participants achieving a PR or better at the end of 4 cycles will continue to receive a total of 8 cycles of combination therapy. Participants with less than PR after completing 4 cycles will go off study therapy. After 8 cycles of therapy, participants who are MRD positive will have the option to receive an ASCT if stem cells were able to be extracted, before initiating maintenance therapy with Lenalidomide for up to 2 years, and patients who are MRD negative will go directly on to receive maintenance therapy with Lenalidomide for up to 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B - Carfilzomib, Lenalidomide and Dexamethasone (KRD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive Carfilzomib, Lenalidomide and Dexamethasone on a 28 day cycle. Participants achieving a PR or better at the end of 4 cycles will continue to receive a total of 8 cycles of combination therapy. Participants with less than PR after completing 4 cycles will go off study therapy. After 8 cycles of therapy, participants who are MRD positive will have the option to receive an ASCT if stem cells were able to be extracted, before initiating maintenance therapy with Lenalidomide for up to 2 years, and patients who are MRD negative will go directly on to receive maintenance therapy with Lenalidomide for up to 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C- Carfilzomib, Lenalidomide and Dexamethasone with Daratumumab (DKrd)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive Carfilzomib, Lenalidomide, Dexamethasone with Daratumumab, Acetaminophen, Diphenhydramine and Montelukast on a 28 day cycle. Participants achieving a PR or better at the end of 4 cycles will continue to receive a total of 8 cycles of combination therapy. Participants with less than PR after completing 4 cycles will go off study therapy. After 8 cycles of therapy, participants who are MRD positive will have the option to receive an ASCT if stem cells were able to be extracted, before initiating maintenance therapy with Lenalidomide for up to 2 years, and patients who are MRD negative will go directly on to receive maintenance therapy with Lenalidomide for up to 2 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>1.3 mg/m2 administered Subcutaneous (SC) or intravenous (IV) on days 1, 4, 8 and 11 of a 21 day treatment cycle for participants randomized to Arm A.</description>
    <arm_group_label>Arm A - Bortezomib, Lenalidomide and Dexamethasone (VRD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>20 mg or 40 mg per dose administered by mouth (PO) or IV.&#xD;
Participants randomized in Arm A:&#xD;
20 mg/dose on days 1, 4, 8 and 11 on a 21 day treatment cycle;&#xD;
Participants randomized in Arm B:&#xD;
Cycles 1 through 4 - 40mg/dose on days 1, 8 and 15 on a 28 day cycle; Cycles 5 through 8 - 20mg/dose on days 1, 8, 15 on a 28 day cycle&#xD;
Participants randomized in Arm C:&#xD;
Cycle 1 - 20 mg/dose on days 1, 2, and 22, and 40mg/dose on days 8 and 15 on a 28 day cycle; Cycle 2 - 40 mg/dose on days 1, 8, and 15 and 20mg/dose o day 22 on a 28 day cycle; Cycles 3-4 - 40mg/dose on Days 1, 8, 15 on a 28 day cycle; Cycles 5-8 - 20mg/dose on days 1, 8, 15 on a 28 day cycle</description>
    <arm_group_label>Arm A - Bortezomib, Lenalidomide and Dexamethasone (VRD)</arm_group_label>
    <arm_group_label>Arm B - Carfilzomib, Lenalidomide and Dexamethasone (KRD)</arm_group_label>
    <arm_group_label>Arm C- Carfilzomib, Lenalidomide and Dexamethasone with Daratumumab (DKrd)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>10 or 25 mg/day capsules administered PO.&#xD;
Participants randomized in Arm A:&#xD;
25 mg/day capsules on Days 1 through 14 of a 21 day cycle.;&#xD;
Participants randomized in Arm B:&#xD;
Cycles 1 through 8 - 25 mg/day capsules on Days 1 through 21 of a 28 day cycle;&#xD;
Participants randomized in Arm C:&#xD;
Cycles 1 - 25 mg/day capsules on Days 2 through 21 of a 28 day cycle; Cycles 2 through 8 - 25 mg/day capsules on Days 1 through 21 of a 28 day cycle;&#xD;
Maintenance Therapy:&#xD;
10 mg capsules on Days 1 through 21 on a 28 days cycle.</description>
    <arm_group_label>Arm A - Bortezomib, Lenalidomide and Dexamethasone (VRD)</arm_group_label>
    <arm_group_label>Arm B - Carfilzomib, Lenalidomide and Dexamethasone (KRD)</arm_group_label>
    <arm_group_label>Arm C- Carfilzomib, Lenalidomide and Dexamethasone with Daratumumab (DKrd)</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>650 mg administered PO.&#xD;
Participants randomized to Arm C:&#xD;
Cycles 1 through 8 - 650 mg administered on Days 1, 8 and 15.</description>
    <arm_group_label>Arm C- Carfilzomib, Lenalidomide and Dexamethasone with Daratumumab (DKrd)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine</intervention_name>
    <description>25 mg administered via IV&#xD;
Participants randomized to Arm C:&#xD;
Cycles 1 through 8 - 25 mg administered on Days 1, 8 and 15.</description>
    <arm_group_label>Arm C- Carfilzomib, Lenalidomide and Dexamethasone with Daratumumab (DKrd)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast</intervention_name>
    <description>10 mg administered PO to participants randomized to Arm C prior to the first 4 doses of Daratumumab.</description>
    <arm_group_label>Arm C- Carfilzomib, Lenalidomide and Dexamethasone with Daratumumab (DKrd)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>20 mg or 56 mg/m2 per dose administered via IV.&#xD;
Participants randomized to Arm B:&#xD;
Cycle 1 - 20 mg/m2 per dose on Day 1 and 56 mg/m2 per dose on days 8 and 15 of a 28 day cycle; Cycles 2 through 8 - 56 mg/m2 per dose on days 1, 8 and 15 of a 28 day cycle;&#xD;
Participants randomized to Arm C:&#xD;
Cycle 1 - 20 mg/m2 per dose on Day 2 and 56 mg/m2 per dose on days 8 and 15 of a 28 day cycle; Cycles 2 through 8 - 56 mg/m2 per dose on days 1, 8 and 15 of a 28 day cycle</description>
    <arm_group_label>Arm B - Carfilzomib, Lenalidomide and Dexamethasone (KRD)</arm_group_label>
    <arm_group_label>Arm C- Carfilzomib, Lenalidomide and Dexamethasone with Daratumumab (DKrd)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>16 mg/kg administered via IV or 1800 mg SC, per treating physician discretion.&#xD;
Participants randomized to Arm C:&#xD;
Cycles 1 though 2 - 16 mg/kg IV or 1800 mg SC on days 1, 8, 15, and 22 of a 28 day cycle; Cycles 3 through 6- 16 mg/kg IV or 1800 mg SC on days 1 and 15 of a 28 day cycle; Cycles 7 through 8 - 16 mg/kg IV or 1800 mg SC on day 1 of a 28 day cycle</description>
    <arm_group_label>Arm C- Carfilzomib, Lenalidomide and Dexamethasone with Daratumumab (DKrd)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Stem Cell Transplant (ASCT)</intervention_name>
    <description>Participants who are MRD positive at the conclusion of 8 cycles of study treatment, and were able to have their stem cells that were extracted, will receive ASCT from participants' bone marrow samples.</description>
    <arm_group_label>Arm A - Bortezomib, Lenalidomide and Dexamethasone (VRD)</arm_group_label>
    <arm_group_label>Arm B - Carfilzomib, Lenalidomide and Dexamethasone (KRD)</arm_group_label>
    <arm_group_label>Arm C- Carfilzomib, Lenalidomide and Dexamethasone with Daratumumab (DKrd)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Newly diagnosed patients with histologically confirmed Multiple Myeloma (MM) based on&#xD;
        the following criteria:&#xD;
&#xD;
          -  Clonal plasma cells in the bone marrow&#xD;
&#xD;
          -  Measurable disease within the past 4 weeks defined by any one of the following:&#xD;
&#xD;
               -  Serum monoclonal protein &gt;/= 1.0 g/dL&#xD;
&#xD;
               -  Urine monoclonal protein &gt;/= 200 mg/24 hour&#xD;
&#xD;
               -  Involved serum immunoglobulin free light chain &gt;/= 10 mg/dL and abnormal&#xD;
                  kappa/lambda ratio 2. Evidence of underlying end organ damage and/or myeloma&#xD;
                  defining event attributed to underlying plasma cell proliferative disorder&#xD;
                  meeting at least one of the following:&#xD;
&#xD;
          -  Hypercalcemia: serum calcium &gt; 0.25 millimoles (mmol) /L (&gt; 1 mg/dL) above upper limit&#xD;
             of normal or &gt;/= 2.75 mmol (11 mg/dL)&#xD;
&#xD;
          -  Anemia: hemoglobin value &lt;10 g/dL or &gt;2 g/dL below lower limit of normal&#xD;
&#xD;
          -  Bone disease &gt;/= 1 lytic lesions on skeletal X-ray, CT, or Positron Emission&#xD;
             Tomography (PET)-CT. For patients with 1 lytic lesion, bone marrow should demonstrate&#xD;
             &gt;/=10% clonal plasma cells&#xD;
&#xD;
          -  Clonal bone marrow plasma cell percentage &gt;/=60%&#xD;
&#xD;
          -  Involved/un-involved serum free light chain ratio &gt;/=100 and involved free light chain&#xD;
             &gt;/=100 mg/L&#xD;
&#xD;
          -  &gt; 1 focal lesion on magnetic resonance imaging study (lesion must be &gt;5mm) in size&#xD;
&#xD;
          -  For patients with 1 lytic lesion, bone marrow should demonstrate ≥10% clonal plasma&#xD;
             cells 3. Creatinine clearance (CrCl) &gt;/=60 ml/min. CrCl can be measured or estimated&#xD;
             using Cockcroft-Gault method, Modification of Diet in Renal Disease (MDRD), or Chronic&#xD;
             Kidney Disease Epidemiology Collaboration (CKD-EPI) formulae 4. Age &gt;/= 18 years at&#xD;
             the time of signing the informed consent documentation. Age limit of &lt;/= 75 years 5.&#xD;
             Eastern Cooperative Oncology Group (ECOG) performance status 0-2 6. Absolute&#xD;
             neutrophil count (ANC) &gt;/= 1.0 K/microliter (uL), hemoglobin &gt;/= 8 g/dL, and platelet&#xD;
             count &gt;/= 75 K/uL, unless if cytopenias are deemed to be due disease at discretion of&#xD;
             clinical investigator. Transfusions and growth factors are permissible.&#xD;
&#xD;
             7. Adequate hepatic function, with bilirubin &lt; 1.5 x the Upper Limit of Normal (ULN),&#xD;
             and Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) &lt; 3.0 x ULN 8.&#xD;
             All study participants must be able to tolerate one of the following&#xD;
             thromboprophylactic strategies: aspirin, low molecular weight heparin or warfarin&#xD;
             (Coumadin) or alternative anti-coagulant 9. All study participants must be registered&#xD;
             into the mandatory electronic REMS (eREMS) program and be willing and able to comply&#xD;
             with the requirements of Risk Evaluation Management and Safety (REMS).&#xD;
&#xD;
             10) Females of childbearing potential (FCBP) must have a negative serum or urine&#xD;
             pregnancy test within 10-14 days and again within 24 hours prior to prescribing&#xD;
             lenalidomide for Cycle 1 (prescriptions must be filled within 7 days) and must either&#xD;
             commit to continued abstinence from heterosexual intercourse or begin two acceptable&#xD;
             methods of birth control, one highly effective method and one additional effective&#xD;
             method at the same time, at least 28 days before she starts taking lenalidomide. FCBP&#xD;
             must also agree to ongoing pregnancy testing. Men must agree to use a latex condom&#xD;
             during sexual contact with a FCBP even if they have had a successful vasectomy.&#xD;
&#xD;
          -  A female of childbearing potential is a sexually mature female who: 1) has not&#xD;
             undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally&#xD;
             postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in&#xD;
             the preceding 24 consecutive months)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients receiving &gt;1 cycle of prior treatment or concurrent systemic treatment for&#xD;
             multiple myeloma:&#xD;
&#xD;
               -  Treatment of hypercalcemia or spinal cord compression or aggressively progressing&#xD;
                  myeloma with current or prior corticosteroids is permitted&#xD;
&#xD;
               -  Bone targeting agents are permitted&#xD;
&#xD;
               -  Concurrent or prior treatment with corticosteroids for indications other than&#xD;
                  multiple myeloma is permitted&#xD;
&#xD;
               -  Prior treatment with radiotherapy is permitted&#xD;
&#xD;
               -  Prior MM treatment, such as Immunomodulating Drugs (IMIDs) or nonn-MM drugs in&#xD;
                  clinical trials for smoldering myeloma is permitted with a washout period of 2&#xD;
                  weeks from last dose. Smoldering patients previously treated carfilzomib are&#xD;
                  excluded&#xD;
&#xD;
               -  Patients with measurable disease who received up to one cycle of any therapy&#xD;
                  within 60 days with a washout period of 2 weeks from last dose (on a trial or&#xD;
                  outside a trial) are eligible (Note: Measurable disease is defined as one or more&#xD;
                  of the following: Serum monoclonal protein ≥ 1.0 g/dL, Urine monoclonal protein ≥&#xD;
                  200 mg/24 hour and/ or Involved serum immunoglobulin free light chain ≥ 10 mg/dL&#xD;
                  AND abnormal kappa/lambda ratio)&#xD;
&#xD;
          2. Plasma cell leukemia&#xD;
&#xD;
          3. Polyneuropathy, Organomegaly, Endocrinopathy, Myeloma protein, and Skin changes&#xD;
             (POEMS) syndrome&#xD;
&#xD;
          4. Amyloidosis&#xD;
&#xD;
          5. Has known chronic obstructive pulmonary disease with a forced expiratory volume in 1&#xD;
             second (FEV1) &lt;50% of predicted normal (note that FEV1 testing is required for&#xD;
             subjects suspected of having chronic obstructive pulmonary disease and subjects must&#xD;
             be excluded if FEV1 &lt;50% of predicted normal).&#xD;
&#xD;
          6. Pregnant or lactating females. Because there is a potential risk for adverse events&#xD;
             nursing infants secondary to treatment of the mother with carfilzomib in combination&#xD;
             with lenalidomide. These potential risks may also apply to other agents used in this&#xD;
             study.&#xD;
&#xD;
          7. Uncontrolled hypertension (i.e. systolic BP &gt;160 mmHg, diastolic BP &gt; 100 mmHg) or or&#xD;
             diabetes&#xD;
&#xD;
          8. Active hepatitis B or C infection&#xD;
&#xD;
          9. Subject is:&#xD;
&#xD;
               -  Seropositive for human immunodeficiency virus (HIV)&#xD;
&#xD;
               -  Seropositive for hepatitis B (defined by a positive test for hepatitis B surface&#xD;
                  antigen [HBsAg]). Subjects with resolved infection (ie, subjects who are HBsAg&#xD;
                  negative but positive for antibodies to hepatitis B core antigen (anti-HBc)&#xD;
                  and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened&#xD;
                  using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus&#xD;
                  (HBV) DNA levels. Those who are PCR positive will be excluded. Exception:&#xD;
                  Subjects with serologic findings suggestive of HBV vaccination (anti-HBs&#xD;
                  positivity as the only serologic marker) AND a known history of prior HBV&#xD;
                  vaccination, do not need to be tested for HBV DNA by Polymerase Chain Reaction&#xD;
                  (PCR).&#xD;
&#xD;
               -  Seropositive for hepatitis C (except in the setting of a sustained virologic&#xD;
                  response (SVR), defined as aviremia at least 12 weeks after completion of&#xD;
                  antiviral therapy).&#xD;
&#xD;
         10. Significant cardiovascular disease with New York Heart Association (NYHA) class III or&#xD;
             IV symptoms, symptomatic ischemia, current uncontrolled arrhythmias, screening ECG&#xD;
             with corrected QT interval (QTc) of &gt; 470 msec, pericardial disease, or myocardial&#xD;
             infarction within 4 months prior to randomization and Left ventricular ejection&#xD;
             fraction &lt; 40% assessed by transthoracic echocardiogram (ECHO),Current unstable angina&#xD;
             as determined by history and physical exam, hypertrophic cardiomyopathy or restrictive&#xD;
             cardiomyopathy&#xD;
&#xD;
         11. Pulmonary hypertension&#xD;
&#xD;
         12. Has refractory Gastrointestinal (GI) disease with refractory nausea/vomiting,&#xD;
             inflammatory bowel disease, or bowel resection that would prevent absorption of oral&#xD;
             agents&#xD;
&#xD;
         13. Uncontrolled intercurrent illness including but not limited to active infection or&#xD;
             psychiatric illness/social situations that would compromise compliance with study&#xD;
             requirements&#xD;
&#xD;
         14. Significant neuropathy &gt;/= Grade 3 or Grade 2 neuropathy with pain at baseline&#xD;
&#xD;
         15. Contraindication to any concomitant medication, including antivirals or&#xD;
             anticoagulation.&#xD;
&#xD;
         16. Major surgery within 3 weeks prior to first dose&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carl Landgren, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philip Arlen</last_name>
    <phone>305-243-5247</phone>
    <email>paa107@miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip Arlen, MD</last_name>
      <phone>305-243-5247</phone>
      <email>paa107@miami.edu</email>
    </contact>
    <investigator>
      <last_name>Carl Landgren, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ken Shain, MD</last_name>
      <phone>888-663-3488</phone>
      <email>Ken.Shain@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Ken Shain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>606012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Agne Paner, MD</last_name>
      <phone>888-352-7874</phone>
      <email>Agne_Paner@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Agne Paner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Comprehensive Cancer Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ariffa Kariapper</last_name>
      <phone>716-845-3838</phone>
      <email>Ariffa.Kariapper@RoswellPark.org</email>
    </contact>
    <investigator>
      <last_name>Jens Hillengass, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neha Korde, MD</last_name>
      <phone>212-639-7664</phone>
      <email>korden@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Neha Korde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stony Brook University</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aisha Hashmi</last_name>
      <phone>631-638-0836</phone>
      <email>Aisha.Hashmi@stonybrookmedicine.edu</email>
    </contact>
    <investigator>
      <last_name>Huda Salman, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elisabet Manasanch, MD</last_name>
      <phone>713-745-8092</phone>
      <email>EEManasanch@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Elisabet Manasanch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institue</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Douglas Sborov, MD</last_name>
      <phone>801-585-2626</phone>
      <email>Douglas.Sborov@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Douglas Sborov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital</name>
      <address>
        <city>Malmö</city>
        <zip>9, 214</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Markus Hannson, MD</last_name>
      <phone>+46 40 33 10 00</phone>
      <email>markus.hansson@med.lu.se</email>
    </contact>
    <investigator>
      <last_name>Markus Hannson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 11, 2020</study_first_submitted>
  <study_first_submitted_qc>February 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2020</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Daratumumab</keyword>
  <keyword>Carfilzomib</keyword>
  <keyword>Lenalidomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

